ASPREE-D: Aspirin for the prevention of depression in the elderly
Michael Berk, RL Woods, MR Nelson, RC Shah, CM Reid, E Storey, SM Fitzgerald, JE Lockery, R Wolfe, M Mohebbi, AM Murray, B Kirpach, R Grimm, JJ McNeil
International Psychogeriatrics | CAMBRIDGE UNIV PRESS | Published : 2016
Awarded by NHMRC
Awarded by US National Institute on Aging
Awarded by Australia's NHMRC
Awarded by National Cancer Institute
The ASPREE-D study is funded by a project grant from the NHMRC (1081901). The ASPREE principal study which recruited participants and is responsible for all follow-up measurements including clinical endpoints, SF-12 and other data capture is funded primarily by a grant from the US National Institute on Aging (1R01AG029824-01A2) with additional support from Australia's NHMRC (ID334047), the Victorian Cancer Agency and Monash University. The ASPREE Healthy Ageing Biobank, which collected the blood samples for measures of inflammatory biomarkers for this study, was funded by a Flagship Cluster Collaboration award from the CSIRO and from the National Cancer Institute through a supplement (5U01AG029824-02 (ASPREE 07210)) to the NIH ASPREE grant. ASPREE is registered on the International Standard Randomized Controlled Trial Number Register (ISRCTN83772183). Bayer Pharma AG provides blinded aspirin and placebo. ASPREE has multiple IRB approvals in the US and Australia. MB is supported by a NHMRC Senior Principal Research Fellowship 1059660. AMM receives research support from the National Institutes of Health. CMR receives research support from the NHMRC (Program grant 1092642) and the Heart Foundation and is supported by a NHMRC Senior Research Fellowship (1045862).